RxDoctor Payments Data

Leopold Kretsch, MD

Family Medicine · Palm Coast, FLNPI 1982136115

Payments from drug & device makers

$3,234in general payments, 2019–2025

Across 137 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$357
  • Bayer$246
  • Otsuka America Pharmaceutical, Inc.$224
  • Idorsia Pharmaceuticals US Inc$184
  • AbbVie$142
  • plus $560 from 11 others

What the payments were for

  • Food & beverage$3,222100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,234 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$133,630
Medicare patients
355
Services billed
1,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$121,116
MounjaroTirzepatide38$80,931
TrulicityDulaglutide38$65,421
EliquisApixaban48$57,533
RybelsusSemaglutide17$35,761
JardianceEmpagliflozin20$24,968
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,572
PremarinEstrogens, Conjugated13$5,846
Potassium Chloride67$4,669
Atorvastatin Calcium355$3,503
Losartan Potassium278$2,899
Rosuvastatin Calcium250$2,787
Gabapentin92$2,346
Levothyroxine Sodium296$2,241
SynthroidLevothyroxine Sodium43$1,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,521$156,877103 claims
Lilly USA, LLCMounjaro, Trulicity$357$146,35276 claims
PfizerEliquis, Premarin$15$63,37961 claims
Boehringer IngelheimJardiance$133$24,96820 claims
GSKTrelegy Ellipta$29$11,57219 claims
AbbVieSynthroid$142$1,84943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Palm Coast

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →